<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512313</url>
  </required_header>
  <id_info>
    <org_study_id>H-19079175</org_study_id>
    <nct_id>NCT04512313</nct_id>
  </id_info>
  <brief_title>A Comparison of Rocuronium 0.3 mg/kg, and 0.9 mg/kg for Induction of Anesthesia in Elderly Patients.</brief_title>
  <official_title>A Single-blinded Multicenter Randomized Interventional Study of Rocuronium 0.3 mg/kg, and 0.9 mg/kg Comparing Onset Time, Duration of Action and Effect on Intubating Conditions in Elderly Patients (≥ 80 Years).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of elderly patients above 80 years is increasing and a large proportion of these&#xD;
      patients will require surgery and anesthesia.&#xD;
&#xD;
      During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate&#xD;
      intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of&#xD;
      residual neuromuscular block when using NMBAs like rocuronium.&#xD;
&#xD;
      The aim of this study is to determine the onset time, duration of action and effect on&#xD;
      intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of elderly patients (&gt;80 years) is increasing and a large proportion of these&#xD;
      patients will require surgery and anesthesia within the next decades. Elderly patients are at&#xD;
      higher risk of major morbidity and mortality and are characterized by a reduction in cardiac&#xD;
      output, liver function and renal function. These physiological changes influence&#xD;
      pharmacodynamics and pharmacokinetics of drugs administered during anesthesia.&#xD;
&#xD;
      Rocuronium is a nondepolarizing neuromuscular blocking drug with an onset time of&#xD;
      approximately 70 s and a clinical duration of action of approximately 50 min. according to&#xD;
      previous studies. During anesthesia rocuronium is administered to facilitate intubating&#xD;
      conditions and reduce the trauma to the larynx and vocal cords. Rocuronium is primarily&#xD;
      metabolized in the liver (70 % unmetabolized via the bile) and excreted via the kidneys.&#xD;
&#xD;
      Onset time and duration of action of rocuronium should be assessed by objective neuromuscular&#xD;
      monitoring. Also, this reduces the risk of residual neuromuscular block which is defined as a&#xD;
      train of four (TOF) ratio less than 0.9. Especially elderly patients have a high incidence of&#xD;
      residual neuromuscular block.&#xD;
&#xD;
      The collected data regarding the effect of rocuronium in elderly patients may change the&#xD;
      treatment so these patients receive the correct dose for optimal intubating conditions. Also,&#xD;
      detection of duration of action of different doses of rocuronium may reduce the risk of&#xD;
      residual block and postoperative respiratory complications&#xD;
&#xD;
      The aim of this study is to determine the onset time, duration of action and effect on&#xD;
      intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rocuronium onset time</measure>
    <time_frame>intraoperative (From start of rocuronium injection to train-of-four (TOF) count of 0)</time_frame>
    <description>Time from start of rocuronium injection to train-of-four (TOF) count of 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of action of rocuronium</measure>
    <time_frame>intraoperative (Time from start of rocuronium injection to reappearance of TOF ratio &gt; 0.9.)</time_frame>
    <description>Time from start of rocuronium injection to reappearance of TOF ratio &gt; 0.9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of intubating conditions ad modum Fuchs-Buder et al</measure>
    <time_frame>intraoperative (From train-of-four (TOF) count of 0 till)</time_frame>
    <description>Intubating conditions are rated by an intubating difficulty scale according to Fuchs-Buder et al.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Neuromuscular Blockade, Residual</condition>
  <condition>Anesthesia</condition>
  <condition>Intubation Complication</condition>
  <arm_group>
    <arm_group_label>Group receiving rocuronium 0,3 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 0,3 mg/kg at induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group receiving rocuronium 0,9 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium 0,9 mg/kg at induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0,3mg/kg</intervention_name>
    <description>Rocuronium 0,3mg/kg at induction</description>
    <arm_group_label>Group receiving rocuronium 0,3 mg/kg</arm_group_label>
    <other_name>Rocuronium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0,9mg/kg</intervention_name>
    <description>Rocuronium 0,9mg/kg at induction</description>
    <arm_group_label>Group receiving rocuronium 0,9 mg/kg</arm_group_label>
    <other_name>Rocuronium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 80&#xD;
&#xD;
          -  Scheduled to elective surgery (expected duration time of surgery &gt; 1 hour) under&#xD;
             general anesthesia with intubation and use of rocuronium.&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification I to III&#xD;
&#xD;
          -  Informed consent (see appendix 1)&#xD;
&#xD;
          -  Read and understand Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuromuscular disease&#xD;
&#xD;
          -  Known allergy to rocuronium&#xD;
&#xD;
          -  Prone position&#xD;
&#xD;
          -  Indication for rapid sequence induction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matias Vested, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesia, Head and Orthopaedics Centre, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Matias Vested</investigator_full_name>
    <investigator_title>Principal Investigator, Anesthesiologist, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

